We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
CorrespondenceMetastatic basal cell carcinoma with neuroendocrine differentiation: complete response to cemiplimab.
- Authors
Marti-Marti, Ignasi; Puig, Susana; Albero-González, Raquel; Masferrer, Emili; Iglesias, Pablo; Pérez-Anker, Javiera; Serra-García, Laura; Tarroch, Xavier; Curcó, Neus; Toll, Agustí
- Abstract
This article discusses a case of metastatic basal cell carcinoma (BCC) with neuroendocrine differentiation (BCCNE) and its response to the immunotherapy drug cemiplimab. BCC is a common type of cancer, but metastatic BCC is rare and has a high mortality rate. The patient in this case had an mBCC with neuroendocrine differentiation, which is a rare histological variant. Previous treatments did not work, but the patient responded well to cemiplimab, leading to complete remission of the cancer. The article suggests that cemiplimab could be a suitable therapeutic option for patients with metastatic BCCNE.
- Subjects
CELL adhesion molecules; MERKEL cell carcinoma; PROSTATE-specific antigen; PULMONARY nodules; INFORMED consent (Medical law)
- Publication
Clinical & Experimental Dermatology, 2024, Vol 49, Issue 9, p1060
- ISSN
0307-6938
- Publication type
Article
- DOI
10.1093/ced/llae099